Nottingham University, UK
Published: 3 Dec 2008
Views: 16534
Prof. Poulam Patel
Extended, escalated dose chemo shows no survival benefit in advanced melanoma.
- Categories:
- Melanoma & skin
Related Videos
Updates in geriatric medical oncology from SIOG meeting
Dr Enrique Soto - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zu...
28 Oct 2020
Treating ALL patients during the COVID-19 pandemic
Prof David Marks - University hospital Bristol NHS Foundation Trust, Bristol, UK
15 Oct 2020
ESMO 2020 melanoma roundup
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
28 Sep 2020
Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or...
Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
22 Sep 2020
COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected st...
Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
30 Jun 2020
IMspire 150: Atezolizumab, cobimetinib and vemurafenib in untreated patients wit...
Prof Grant McArthur - Peter MacCallum Cancer Center, Melbourne, Australia
1 May 2020
Continuous vs intermittent dosing of dabrafenib and trametinib in BRAF mutated m...
Prof Alain Algazi -University of California San Francisco, San Francisco, USA
30 Apr 2020
